MedTrace Logo

Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause

NCT02943655 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-06-04

No results posted yet for this study

Summary

Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow, frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic disease.

Conditions

  • Improve Quality of Life
  • Heavy Menstrual Bleeding

Interventions

DRUG

combined contraceptive pills (microcept)

oral combined contraceptive once daily

DRUG

medroxyprogesterone acetate (progest)

oral 5 mg medroxyprogesterone acetate daily

DRUG

mefenamic acid (ponstan forte)

oral 500 mg mefenamic acid three times per day

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2020-10-10
Completion
2021-02-10

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943655 on ClinicalTrials.gov